Brokers Issue Forecasts for Teladoc Inc’s FY2017 Earnings (TDOC)

Teladoc Inc (NYSE:TDOC) – Equities researchers at Oppenheimer raised their FY2017 EPS estimates for shares of Teladoc in a research note issued to investors on Tuesday. Oppenheimer analyst M. Naidu now forecasts that the health services provider will earn ($1.54) per share for the year, up from their previous forecast of ($1.56). Oppenheimer currently has a “Outperform” rating and a $45.00 target price on the stock. Oppenheimer also issued estimates for Teladoc’s Q4 2017 earnings at ($0.40) EPS, Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.17) EPS, FY2018 earnings at ($1.12) EPS, Q1 2019 earnings at ($0.24) EPS, Q2 2019 earnings at ($0.22) EPS, Q3 2019 earnings at ($0.19) EPS, Q4 2019 earnings at ($0.10) EPS and FY2019 earnings at ($0.75) EPS.

Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). Teladoc had a negative net margin of 45.64% and a negative return on equity of 29.70%. The company had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same quarter last year, the company posted ($0.33) EPS. Teladoc’s revenue was up 112.0% on a year-over-year basis.

A number of other equities research analysts also recently commented on TDOC. KeyCorp reiterated a “buy” rating and set a $37.00 price objective on shares of Teladoc in a research report on Sunday, September 17th. Robert W. Baird downgraded Teladoc from an “outperform” rating to a “neutral” rating and increased their price objective for the company from $14.00 to $36.00 in a research report on Monday, September 18th. Zacks Investment Research upgraded Teladoc from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “hold” rating and set a $31.00 price objective on shares of Teladoc in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $42.00 price objective on shares of Teladoc in a research report on Friday, September 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $39.31.

Shares of Teladoc (TDOC) opened at $32.65 on Thursday. Teladoc has a 52-week low of $15.65 and a 52-week high of $38.40. The company has a market capitalization of $1,980.00 and a price-to-earnings ratio of -22.52. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.

In other news, CFO Mark Hirschhorn sold 30,000 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $989,700.00. Following the transaction, the chief financial officer now directly owns 5,203 shares of the company’s stock, valued at $171,646.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 100,000 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the transaction, the chief executive officer now directly owns 718,261 shares in the company, valued at $23,695,430.39. The disclosure for this sale can be found here. Insiders sold 210,000 shares of company stock valued at $6,889,350 in the last 90 days. Corporate insiders own 4.47% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Trust N.A. increased its stake in shares of Teladoc by 36.2% in the third quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock worth $330,000 after acquiring an additional 2,643 shares during the last quarter. American International Group Inc. increased its stake in shares of Teladoc by 8.1% in the third quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock worth $1,196,000 after acquiring an additional 2,697 shares during the last quarter. Swiss National Bank increased its stake in shares of Teladoc by 4.8% in the second quarter. Swiss National Bank now owns 59,500 shares of the health services provider’s stock worth $2,065,000 after acquiring an additional 2,700 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after acquiring an additional 2,707 shares during the last quarter. Finally, Brown Advisory Inc. increased its stake in shares of Teladoc by 38.3% in the third quarter. Brown Advisory Inc. now owns 10,521 shares of the health services provider’s stock worth $348,000 after acquiring an additional 2,915 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/13/brokers-issue-forecasts-for-teladoc-incs-fy2017-earnings-tdoc.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Earnings History and Estimates for Teladoc (NYSE:TDOC)

What are top analysts saying about Teladoc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teladoc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit